I have had a Google Alert for DMAPT, the parthenolide analogue (see my page on this topic), for ages, now. Whenever I receive a Google Alert on DMAPT, I get all excited, only to discover that it frequently is about a meeting of the Detroit Metropolitan Area Physics Teachers. Aaargh! I am also on a Leukemia and Lymphoma Society alert list for the DMAPT clinical trial, which was supposed to begin months ago in the UK. Until this morning, though, I hadn’t even heard a whisper about the clinical trial that was supposed to begin months ago in the UK.
Well, early this morning I discovered why. A blogging friend, Dave, to whom I owe an immense debt of gratitude!, informed me that the acronym DMAPT has been changed to LC-1. You’ve got to be kidding….double-aaargh!
Okay, but let’s not get lost in trivial matters, because, guess what?, dramatic drum roll!: the LC-1 clinical trial has begun. Yes indeedie…it began…a few weeks ago…at Cardiff University…in the UK! Hah! I am absolutely delighted, of course.
I began doing research immediately, but the more I looked the more I was puzzled. Some sources referred to DMAPT and LC-1 as the same exact thing, whereas others (http://tinyurl.com/dl7go3) called it a novel dimethylamino-parthenolide analogue. An analogue of…an analogue? That made no sense. Moreover, I was left with the doubt that, unlike DMAPT, LC-1 might not attack the leukemic stem cells. I found no mention of this anywhere, you see.
So I decided to write to one of the top DMAPT researchers (with whom I corresponded briefly last year), who responded within a few hours in spite of the time difference between the U.S. and Italy. Lovely person, incidentally. Well, it’s simple enough, and I quote from the researcher’s e-mail: LC-1 is simply the commercial designation for DMAPT, they are the same drug. Phew! Relief!
The most recent LC-1 news release that I could find is the one that Dave sent to me this morning (the DMAPT researcher sent me the same link, thank you!): http://tinyurl.com/blzqcs As you can see, apart from confirming that the trial has actually begun!, the main titbit is that so far LC-1 has been well tolerated by the patients in the study. Good!
Note: LC-1 is not a new acronym, by the way (how could I have missed that??? Dear, dear…). I came across this “Molecular Cancer Therapeutics” study that was published in 2007: http://tinyurl.com/ctuzj8. LC-1 was tested, successfully, together with Sulindac, a COX inhibitor, against pancreatic cancer in vitro and in vivo (= mice).
Well, we will just have to be sit back and be patient for a while…but you can rest assured that I will change my Google Alert…! Che roba!
MARGARET: I HAVE MYELODYSPLESIA AND I HAVE BEEN CORRESPONDING WITH DR. CRAIG JORDAN FROM UNIVERSITY OF ROCHESTER AND HE TOLD ME THAT IF EVERYTHING GOES WELL THE TRIALS IN THE US, WILL BE STA RTING NEXT YEAR!. I HAVE BEEN FOLLOWING PARTHENOLIDE MYSELF FOR A FEW YEARS. I AM ALSO VERY EXCITED. I WILL LET YOU KNOW THE LATEST THAT I FIND OUT. TAKE CARE BERTA